Work

Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?

Year: 2019

Type: article

Abstract: Intratumoral immunomodulation is emerging as an attractive strategy to deliver immunotherapeutic agents directly into the tumor microenvironment as a means to potentiate systemic anti-tumor immune response. In this issue of Molecular Therapy, two studies have explored such an approach by using viral vectors to deliver anti-programmed death ligand-1 (aPDL1) antibody or a fusion protein of soluble programmed cell death protein 1 (PD-1) linked to CD137 ligand (CD137L).1,2 These studies demonstrate that the success of such strategies is dependent on the type of vector used for ligand delivery and provide evidence that, within such a context, a fusion ligand encoded by a single vector may be superior to a combination of vectors encoding the individual ligands separately.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2019.09.022

Author: Dmitriy Zamarin

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,500